Research opportunities for other movement disorders
Have you been diagnosed with probable or possible Progressive Supranuclear Palsy (PSP)?
OHSU is conducting an observational study in order to determine why patients with PSP fall. The purpose of this study is to learn more about falls and balance dysfunction in PSP to improve quality of life and help guide rehabilitation strategies for individuals with PSP. An observational study means that study participants will undergo numerous tests and assessments of bodily processes related to PSP, but will not receive an experimental drug or treatment.
Participation in this study will require one phone visit to determine eligibility, followed by one visit to the clinic for balance testing. To qualify, subjects must have a diagnosis of probable or possible PSP, be able to stand unassisted for 5 minutes, able to walk unassisted for 50 ft, and be between the ages of 40-85 years. If interested, please contact Mike Fleming, 503-346-0842 or firstname.lastname@example.org. IRB# 7924
Do you have cervical dystonia (CD) and are currently being treated with Botox? Is the therapeutic benefit of your injections lasting less than 10 weeks?
This study is looking at the therapeutic benefit of Xeomin, which is an FDA approved drug used to treat cervical dystonia, similar to Botox. The current standard of care for this treatment of CD includes injections into the affected neck muscles every 12 weeks. However, there is evidence to suggest that some patients may be experiencing significant loss of treatment effect within 10 weeks of injection. The purpose of this study is to evaluate the safety and efficacy of Xeomin in a short dosing period (6-10 weeks).
Participation in this study will last approximately 30-32 months and include 12-17 clinic visits. Subjects will be randomly assigned to participate in either the short dosing group (injections every 6-10 weeks) or the long dosing group (injections every 12 weeks). To qualify for this study, you must be diagnosed with cervical dystonia, received a least 3 Botox treatment injections over the last year, and receiving less than 10 weeks of treatment effect. Subjects will receive payment for their participation in this trial. Dr. Matthew Brodsky is the investigator for this study. For more information, please contact Kellie Kenis at 503-494-9531 or email@example.com. IRB# 8241